Triatomic Management’s DexCom DXCM Stock Holding History

Triatomic Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-70,000	Closed	-$6.53M	–	44
2023 Q3	$6.53M	Buy	+70,000	New	+$7.89M	4.51%	9

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Triatomic Management's DXCM Position: Q4 2023 in Review

Triatomic Management sold out of DexCom (DXCM) in Q4 2023, closing a stake of 5,000 shares — an estimated $467K sold.

Triatomic Management first reported a position in DXCM in Q4 2021 and held it in 2 quarters. The position peaked at $1.88M in Q4 2021. 974 funds tracked by Wall St. Rank hold DXCM as of Q4 2023.

Triatomic Management reported no remaining DexCom position as of Q4 2023 after selling out during the quarter.
Triatomic Management sold 5,000 DexCom shares in Q4 2023, an estimated $467K.
Triatomic Management first reported a position in DexCom in Q4 2021 and held it in 2 quarters.
Triatomic Management's DexCom position peaked at $1.88M in Q4 2021.
974 funds tracked by Wall St. Rank held DexCom as of Q4 2023.

Based on Triatomic Management's 13F filing for Q4 2023, filed 13 Feb 2024.